News
Videos
Conferences
Events
Resources
Subscribe

|Videos|September 27, 2017

What is BCG Immunotherapy?

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Image of "FDA"

FDA Approves Keytruda and Padcev for Muscle Invasive Bladder Cancer

BySpencer Feldman

November 21st 2025

leading oncology experts

Cancer Experts Share Emerging Treatments Patients Should Know in 2026

November 12th 2025

Trial data showed a 62% complete response rate at 6 months with detalimogene coraplasmid among patients with high-risk, BCG-unresponsive bladder cancer.

Detalimogene Shows 62% Response Rate in Bladder Cancer Trial

BySpencer Feldman

November 12th 2025

Image of people.

Experts Discuss Next Steps in Perioperative Bladder Cancer Treatment

ByDr. Joshua K. Sabari,Dr. Petros Grivas ,Chandler H. Park, MD

November 11th 2025

Dr. Minetta Liu

Signatera Guides Bladder Cancer Treatment After Surgery

BySpencer Feldman

November 11th 2025

Trending on CURE

B7-H3 CAR T-Cell Therapy Shows Acceptable Safety in Recurrent Glioblastoma

Early Real-World Uptake of Voranigo in Patients With IDH-Mutant Glioma

Giredestrant Shows Benefit for Early Breast Cancer in Phase 3 Trial

Gomekli Shows Early Activity in Pediatric Low Grade Glioma

Voranigo Plus Temodar Found to Be Safe in Patients With IDH1/2+ Glioma

© 2025 MJH Life Sciences^®

All rights reserved.